Clinically-validated products for thehealthjourney

Bringing
Our
Science
to
Market

DISRUPTING
THE
WELLNESS
LANDSCAPE
USING
CLINICAL
TESTING
WITH
THE
SAME
RIGOR
AS
PHARMACEUTICAL
PRODUCTS

Swipe
Solarea's medical foods
Pharmaceuticals
Supplements
FDA formulation requirements
Mandates in vitro testing
Mandates pre-clinical trials
Mandates clinical trials
Jump To:
Launched
SBD111

SBD111

Clinically validated to slow bone loss (clinical study pending peer review & publication)

Toggle for Pipeline

Our
first
product
Bondia™
was
clinically
validated
to
slow
bone
loss
(clinical
study
pending
peer
review
&
publication)

Findings
of
Bondia™

Abstract

SBD111

Bone loss is one of many health conditions exacerbated by inflammation. By harnessing the probiotic potential of fruit- and vegetable-derived microbes, Bondia™ targets the inflammatory signals that trigger bone degradation, while simultaneously strengthening the gut barrier to reduce further inflammation.

In Vitro Testing

?

Findings

Through in vitro testing, Bondia™ was shown to increase gut barrier integrity, reduce inflammatory cytokine production from gut and immune cells, and reduce the activity of osteoclasts, specialized bone resorbing cells, in culture.

Preclinical

?

Findings

Through preclinical testing, increased concentrations of Bondia™ were shown to reduce bone loss, lessen inflammation, and reduce markers of bone turnover. Together, these results are indicative of Bondia™’s ability to reduce bone loss.

Clinical

?

Findings

Bondia™ was recently evaluated for efficacy in a large randomized, double-blind, placebo-controlled clinical food trial in 286 early postmenopausal women. The study demonstrated Bondia™'s ability to slow bone loss in a prespecified population. The results are pending peer review and publication.

July 2025

SBD121

Being developed to address the dietary needs of rheumatoid arthritis

Toggle for Pipeline

SBD121
our
second
innovation
currently
being
evaluated
in
a
clinical
trial
is
designed
for
the
dietary
management
of
rheumatoid
arthritis
by
reducing
inflammation.

Findings
of
SBD121

Abstract

SBD121

Developed to be taken alongside the standard-of-care drug methotrexate, SBD121 is our Defined Microbial Assemblage (DMA™) that is currently undergoing clinical validation for the dietary management of rheumatoid arthritis as well as the gastrointestinal side effects of methotrexate.

In Vitro Testing

?

Findings

Through in vitro tests, our candidate SBD121 was shown to increase gut barrier integrity, which can help the body better address the inflammation associated with rheumatoid arthritis. SBD121 was also shown to decrease inflammatory signals that can worsen rheumatoid arthritis symptoms.

Preclinical

?

Findings

In preclinical testing, SBD121 was found to reduce arthritis severity scores when consumed daily with methotrexate. Compared to methotrexate alone, usage of SBD121 in conjunction with methotrexate improved arthritis scores by approximately 50%.

Clinical

?

Underway

SBD121 is currently being evaluated through a large randomized, double-blind, placebo-controlled clinical food trial enrolling early-stage rheumatoid arthritis subjects. Subjects are instructed to consume SBD121 twice-daily along with methotrexate. Through the clinical trial, SBD121 medical food will be evaluated for the dietary management of joint pain, swelling, inflammatory signals and gut barrier function.

In
development

TBD

SBDXXX

Being developed to address the dietary needs of psoriatic arthritis

Toggle for Pipeline
TBD

SBDXXX

Being developed to address the dietary needs of cellular aging

Toggle for Pipeline